Edentulous Patients Requiring an Implant-supported Rehabilitation, Patients Requiring an Implant-supported Rehabilitation
Conditions
Brief summary
Dental implants are considered a predictable rehabilitation option for tooth extraction or missing teeth. The use of dental implants has evolved into a viable prosthetic alternative to conventional tooth-supported fixed prostheses or removable dentures, with advantages in terms of patient satisfaction and quality of life. Long-term studies have reported excellent success and survival rates for implants used in prosthetic rehabilitation. Benefits in terms of patient satisfaction and preservation of adjacent tooth structure are among the advantages of implant-supported restorations over prosthetic alternatives. However, dental implants can be subject to mechanical and biological complications. After the first year of function, marginal bone loss is minimal around most oral implants. Nevertheless, marginal bone loss or the onset of bacterial-related biological complications, such as mucositis and peri-implantitis, can occur. Despite the growing number of publications in the field of implant rehabilitation, to date only a few studies have investigated the outcomes of implant rehabilitation in a hospital setting characterized by patients with concomitant or previous systemic therapies and pathologies. The objective of this study is to evaluate the success of implant therapy, peri-implant marginal bone resorption (MBL), clinical parameters of peri-implant health, aesthetic parameters of rehabilitation, and patient-reported treatment outcomes in a sample of patients treated in a hospital setting.
Interventions
None listed
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients requiring implant surgery for edentulous rehabilitation; * Age \> 18; * Achievement of FMPS and FMBS ≤ 15%; * Signed written informed consent to participate in the study.
Exclusion criteria
* Uncontrolled diabetes or hypertension; * Uncontrolled periodontal disease; * Inability to perform consistent and continuous follow-up; * Pregnancy or breastfeeding; * Inability to provide written informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peri-implant marginal bone loss | From Implant placement to 5 year follow up. | Measurements were performed in millimeters using intraoral radiographs. |
| Implant survival rate | From Implant placement to 5 year follow up. | Rate of dental implants remaining in situ, measured as a proportion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Implant success rate | From Implant placement to 5 year follow up. | Absence of biological and technical complications, expressed as a proportion. |
| Prosthesis survival rate | From Implant placement to 5 year follow up. | Rate of prostheses remaining in situ, expressed as a proportion. |
| Prosthesis success rate | From Implant placement to 5 year follow up. | Absence of technical complications, expressed as a proportion. |
| Esthetic evaluation | From Implant placement to 5 year follow up. | Assessed using the PES/WES esthetic index. Scores range from 0 to 14 for the PES and from 0 to 10 for the WES, with higher scores indicating better esthetic outcomes. |
| Patient-Reported Outcome Measures | From Implant placement to 5 year follow up. | Recorded using a specifically designed questionnaire and measured with a visual analogue scale (VAS) ranging from 0 to 10, with higher scores indicating better outcomes. |
| Volumetric analysis | From Implant placement to 5 year follow up. | Assessed by superimposing the baseline volume with the volume recorded during follow-up using intraoral scans, measured in cubic millimeters. |
| Glycated hemoglobin level | From Implant placement to 5 year follow up. | Analysis of glycated hemoglobin levels recorded at baseline and during follow-up. |
| Diabetes | From Implant placement to 5 year follow up. | Analysis of the influence of diabetes during follow-up. |
| Influence of medications relevant to bone/tissue metabolism | From Implant placement to 5 year follow up. | Analysis of the influence of medications relevant to bone and tissue metabolism. |
| Osteoporosis | From Implant placement to 5 year follow up. | Analysis of influence of osteoporosis. |
| Cardiovascular disease | From Implant placement to 5 year follow up. | Analysis of influence of cardiovascuar disease. |
| Complete Blood Count | From Implant placement to 5 year follow up. | Analysis of the influence of complete blood count parameters. |
Contacts
CONTACTCarlo Lajolo, MD, DDS
PRINCIPAL_INVESTIGATORCarlo Lajolo
Fondazione Policlinico Universitario A. Gemelli, IRCCS
Outcome results
None listed